American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on (S)-adenosylhomocysteine (AHCY) inhibitors for the treatment of Alzheimer's disease, 2,4-diphenyl-1H-imidazole analogs as cannabinoid CB2 agonists for the treatment of pain, checkpoint kinase 1 (Chk1) and Aurora kinase B as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as VEGFR2 inhibitors, and Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. Investigational drugs discussed include L-002259713 (Merck & Co), AZD-1480 (AstraZeneca), CYT-387 (YM Biosciences) and ruxolitinib (Incyte).
Kibble
Alexandra
A
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. alexandra.kibble@thomsonreuters.com
D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D004358:Drug Therapy; D015507:Drugs, Investigational / Q000494:pharmacology*; D006801:Humans; D009196:Myeloproliferative Disorders / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D004364:Pharmaceutical Preparations / Q000737:chemistry*
D015507:Drugs, Investigational; D004364:Pharmaceutical Preparations